glioblastoma

Link Between DNA Variations And Glioblastoma Found

harminka — Sun, 05 Jul 2009 13:06:46 -0500

Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as glioblastoma. The findings are reported in the current online issue of Nature Genetics.

New Drug Shows Promise For Brain Cancer Treatment

harminka — Thu, 28 May 2009 11:15:08 -0500

An experimental drug derived from cottonseeds shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of Alabama at Birmingham (UAB).

Researchers develop novel glioblastoma mouse model

harminka — Sun, 04 Jan 2009 13:35:58 -0600

Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma—the most common and deadly brain cancer in humans—that closely resembles the development and progression of human brain tumors that arise naturally.

A molecule that targets brain tumors

harminka — Mon, 29 Dec 2008 13:05:50 -0600

UC Davis Cancer Center researchers report today the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer. The finding, which is published in the January 2009 issue of the European Journal of Nuclear Medicine and Molecular Imaging, provides hope for effectively treating an incurable cancer.

New multi-kinase inhibitor trial shows activity in thyroid cancer

harminka — Thu, 23 Oct 2008 07:40:01 -0500

Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumour shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial.

New regulatory circuit identified for aggressive, malignant brain tumor

harminka — Mon, 07 Apr 2008 11:37:39 -0500

Research using a newly developed algorithm has significantly advanced understanding of the molecular events associated with the most common primary brain tumor in adults, human glioblastoma (GBM).

Switch for programmed cell death promotes spread of glioblastoma

harminka — Tue, 11 Mar 2008 14:42:09 -0500

Malignant tumors have usually lost their ability to destroy themselves by programmed cell death, or apoptosis. Therefore, tumors are often resistant to chemotherapy or radiation therapy, whose effect is based on forcing tumor cells to commit suicide.

Gene plays 'Jekyll and Hyde' in brain cancer

harminka — Thu, 07 Feb 2008 11:03:33 -0600

Perhaps the only positive spin one can put on the brain cancer glioblastoma is that it’s relatively uncommon. Other than that, the news is bad. It is nearly always fatal, it tends to strike people in the prime of their lives, and the limited treatment options have changed little over decades.

Tailoring glioblastoma therapies: 1 size does not fit all

harminka — Thu, 07 Feb 2008 11:01:09 -0600

An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard Medical School lends new insight into how the unique genetic signature of glioblastoma tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths in the young and middle-aged population.

Pharmaceutical market fails pregnant women; and more

harminka — Tue, 22 Jan 2008 05:40:21 -0600

In a clinical trial published this week in PLoS Medicine, Charles Sawyers and colleagues looked at the safety of a drug called rapamycin in a selected group of patients who were undergoingsurgery after recurrence of glioblastoma (a highly malignant tumor of the brain).

Vorinostat shows anti-cancer activity in recurrent gliomas

harminka — Mon, 04 Jun 2007 11:36:08 -0500

North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme. These findings were presented today at the American Society of Clinical Oncology Annual Meeting by Eva Galanis, M.D. a Mayo Clinic oncologist and lead investigator of the study.

AZD2171,normalizes tumor vasculature and alleviates edema in glioblastoma patients

harminka — Tue, 17 Apr 2007 12:01:19 -0500

A phase II clinical trial of an angiogenesis inhibitor to treat glioblastoma has shown promise in a majority of patients tested, say researchers at Massachusetts General Hospital and Harvard Medical School. But they also say that the novel imaging and biomarker studies they performed as treatment was underway have revealed why the treatment, AZD2171, ultimately failed, and what might improve the response.